RGEN — Repligen Corporation stock price and chart

Share this page

RGEN

$175.42-4.75%

as of close, Oct 16, 2026

☾ AH $175.42 -4.75%

Repligen CorporationStock · HealthcareNasdaq Composite 0.02%Russell 1000 0.01%Russell 3000 0.01%US Stock Market 0.01%

PeersMRNALLYMDTUNHJNJTMO

Technical analysis2

Overlay lines0

Addendum charts0

VolumeEEEE

20162019202120242026

50.0100.0150.0200.0250.0300.005.0M10.0M$175.42

2026-10-16

Price$175.42

MA20$150.59

MA50$144.45

Vol7.0M

What would $1,000 invested in RGEN be worth today? →

RGEN returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $175.42
YTD price return: +7.05%
YTD total return: +7.05%
Next earnings: Oct 27, 2026 · Before open
Market cap: 9.9B2016-12 1B2026-10 9.9B+849.4% over the window
Enterprise value: 9.8B
Shares outstanding: 56.4M2016-06 33.8M2026-06 56.4M+67.0% over the window
52W low: $100.99
52W high: $198.87
From 52W high: -11.79%
From 52W low: +73.70%
52W range: 76%

Volume

Rel volume: 1.00×
30D volume: 1.2M
30D $ vol: 215.5M

Fundamentals

Sales (ttm): 785.1M2016-06 95.5M2026-06 785.1M+721.9% over the window
Sales/share: $13.912016-06 $2.832026-06 $13.91+392.0% over the window
EPS (ttm): $0.732016-06 $0.252026-06 $0.73+193.4% over the window
FCF (ttm): 112M2016-06 14.4M2026-06 112M+677.8% over the window
FCF/share: $1.982016-06 $0.432026-06 $1.98+365.6% over the window
Book value/share: $37.422016-06 $4.852026-06 $37.42+672.3% over the window
Net margin: 5.29%2016-06 8.7%2026-06 5.3%-39.1% over the window
ROE: 1.97%2016-06 5.1%2026-06 2.0%-61.2% over the window
ROA: 1.41%2016-06 2.9%2026-06 1.4%-52.1% over the window
Debt / equity: 0.26×2024-12 0.272026-06 0.26-2.1% over the window
Current ratio: 9.052016-06 10.212026-06 9.05-11.3% over the window

Growth (CAGR, ttm) · 10Y

Sales: +16.50%2025-06-30 → 2026-06-30674M → 785.1M (+16.5% total)+3.31%2023-06-30 → 2026-06-30712.1M → 785.1M (+10.3% total)+9.08%2021-06-30 → 2026-06-30508.5M → 785.1M (+54.4% total)+23.45%2016-06-30 → 2026-06-3095.5M → 785.1M (+721.9% total)
Net income: n/a-30.59%2023-06-30 → 2026-06-30124.3M → 41.5M (-66.6% total)-16.10%2021-06-30 → 2026-06-3099.9M → 41.5M (-58.4% total)+17.48%2016-06-30 → 2026-06-308.3M → 41.5M (+400.5% total)
FCF: +2.79%2025-06-30 → 2026-06-30108.9M → 112M (+2.8% total)+3.89%2023-06-30 → 2026-06-3099.9M → 112M (+12.1% total)+20.52%2021-06-30 → 2026-06-3044M → 112M (+154.3% total)+22.77%2016-06-30 → 2026-06-3014.4M → 112M (+677.8% total)
Shares: +0.32%2025-06-30 → 2026-06-3056.3M → 56.4M (+0.3% total)+0.40%2023-06-30 → 2026-06-3055.8M → 56.4M (+1.2% total)+0.53%2021-06-30 → 2026-06-3055M → 56.4M (+2.7% total)+5.27%2016-06-30 → 2026-06-3033.8M → 56.4M (+67.0% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: n/a-34.62%2022-12-31 → 2026-06-30$3.24 → $0.73 (-77.4% total)-16.35%2021-06-30 → 2026-06-30$1.79 → $0.73 (-59.0% total)+11.36%2016-06-30 → 2026-06-30$0.25 → $0.73 (+193.4% total)
Sales/share: +16.14%2025-06-30 → 2026-06-30$11.98 → $13.91 (+16.1% total)+2.89%2023-06-30 → 2026-06-30$12.77 → $13.91 (+8.9% total)+8.51%2021-06-30 → 2026-06-30$9.25 → $13.91 (+50.4% total)+17.28%2016-06-30 → 2026-06-30$2.83 → $13.91 (+392.0% total)
FCF/share: +2.47%2025-06-30 → 2026-06-30$1.94 → $1.98 (+2.5% total)+3.47%2023-06-30 → 2026-06-30$1.79 → $1.98 (+10.8% total)+19.90%2021-06-30 → 2026-06-30$0.80 → $1.98 (+147.7% total)+16.63%2016-06-30 → 2026-06-30$0.43 → $1.98 (+365.6% total)
Book value/share: +2.12%2025-06-30 → 2026-06-30$36.65 → $37.42 (+2.1% total)+2.16%2023-06-30 → 2026-06-30$35.10 → $37.42 (+6.6% total)+5.12%2021-06-30 → 2026-06-30$29.16 → $37.42 (+28.3% total)+22.68%2016-06-30 → 2026-06-30$4.85 → $37.42 (+672.3% total)
Price: +13.51%2025-10-16 → 2026-10-16$154.55 → $175.42 (+13.5% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+4.63%2023-10-16 → 2026-10-16$153.16 → $175.42 (+14.5% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-8.05%2021-10-15 → 2026-10-16$266.92 → $175.42 (-34.3% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+19.58%2016-10-14 → 2026-10-16$29.32 → $175.42 (+498.3% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +13.51%2025-10-16 → 2026-10-16$154.55 → $175.42 (+13.5% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+4.63%2023-10-16 → 2026-10-16$153.16 → $175.42 (+14.5% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-8.05%2021-10-15 → 2026-10-16$266.92 → $175.42 (-34.3% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+19.58%2016-10-14 → 2026-10-16$29.32 → $175.42 (+498.3% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 239.2×2016-12 150.742026-10 238.32+58.1% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 153.2×2016-12 71.932026-10 153.22+113.0% over the window
Fwd P/E: 65.8×
P/S (ttm)Market cap ÷ TTM revenue.: 12.6×2016-12 10.392026-10 12.61+21.4% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 4.7×2016-12 6.262026-10 4.69-25.1% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 88.4×2016-12 213.492026-10 88.41-58.6% over the window
EV/EBITDA (fy): 68.3×
EV/Sales (ttm): 12.5×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 1.13%2016-09 0.5%2026-06 1.5%+210.4% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 56.4M ÷ 56.3M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -0.32%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-0.32%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($7B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -0.32%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($0) ÷ today's market cap ($9.9B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 0.00%2016-09 0.0%2026-06 0.0%
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $0 + TTM dividends $0) ÷ today's market cap ($9.9B). Same caveat as the cash buyback yield.: 0.00%2016-09 0.0%2026-06 0.0%

Vs own 10Y history

P/E: 82nd
P/OI: 73rd
P/S: 40th
P/B: 48th
P/FCF: 30th

Bar = where today’s multiple sits in RGEN’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-16#

-4.75%

+0.89%

+1.45%

+18.09%

YTD

+7.05%

+13.50%

-34.28%

Financial statements

Open full RGEN financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+10.48%	+0.43%
JNJ	Johnson & Johnson	-4.38%	+0.90%
ABBV	AbbVie Inc.	+8.73%	+0.71%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+6.97%	-1.29%
MRK	Merck & Co. Inc.	+0.72%	+0.52%
NVS	Novartis AG	+8.59%	+0.16%
TMO	Thermo Fisher Scientific Inc.	+6.41%	-0.93%
AMGN	Amgen Inc.	+14.92%	-0.35%

RGEN — Repligen Corporation price, chart and key statistics